Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
about
Co-expression of AFAP1-AS1 and PD-1 predicts poor prognosis in nasopharyngeal carcinomaPrognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review.Aligning Digital CD8(+) Scoring and Targeted Next-Generation Sequencing with PD-L1 Expression: A Pragmatic Approach in Early-Stage Squamous Cell Lung Carcinoma.Treating KRAS-mutant NSCLC: latest evidence and clinical consequences.Biology of invasive mucinous adenocarcinoma of the lung.Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA.EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer.Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis.Implications of the tumor immune microenvironment for staging and therapeutics.An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.[Clinical Development of Immune Checkpoint Inhibitors in Patients with Small Cell Lung Cancer].APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.Genomics of NSCLC patients both affirm PD-L1 expression and predict their clinical responses to anti-PD-1 immunotherapy.Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis.Correlation between lower balance of Th2 helper T-cells and expression of PD-L1/PD-1 axis genes enables prognostic prediction in patients with glioblastoma.BRCA1/2 and TP53 mutation status associates with PD-1 and PD-L1 expression in ovarian cancer.Clinical characteristics of non-small cell lung cancer harboring mutations in exon 20 of EGFR or HER2.[Research Progress of KRAS Mutation in Non-small Cell Lung Cancer].VISTA expression associated with CD8 confers a favorable immune microenvironment and better overall survival in hepatocellular carcinoma.Immunotherapy in the Asiatic population: any differences from Caucasian population?TP53 Mutation as Potential Negative Predictor for Response of Anti-CTLA-4 Therapy in Metastatic Melanoma.Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan.Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?The Tumor Mutational Burden of Chinese Advanced Cancer Patients Estimated by a 381-cancer-gene Panel.Clinical observation of immune checkpoint inhibitors in the treatment of advanced pancreatic cancer: a real-world study in Chinese cohortNew advances in immunotherapy for non-small cell lung cancerQ56893519Checkpoint blockade-based immunotherapy in the context of tumor microenvironment: Opportunities and challengesRole of Immunotherapy for Oncogene-Driven Non-Small Cell Lung CancerPredictive biomarkers for tumor immune checkpoint blockadePROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?PROS: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?
P2860
Q33889053-5216C8FD-4585-413A-8F75-8E80E3933648Q38774624-8A8E958E-F24E-4167-9D70-C0BD0D8CAC40Q40496586-29C834D6-B87E-49AF-87A3-E43C13C13DE7Q42820759-1BF7E426-030D-4548-A2FB-D88B8EAA653CQ43874020-66EA8C19-2AE6-4316-87E4-561660C1F431Q47143491-92AC4A11-02DE-450B-8978-8A616DAA3366Q47214499-3856DD37-734E-452C-B71A-6561A0FD41ECQ47262054-821CC448-A9F1-4AD1-A773-B28A2CC16B22Q47592007-9E1D7D2E-7087-4BB2-841D-CE745D98D35DQ49667322-AB56378A-D248-4315-9D21-BC95D789ABABQ49887897-B56455B6-36F6-4EC5-90E5-E302470A9536Q49958933-0CE3AB85-7ED5-4E6C-8EEB-9409D67D9265Q52562762-3583E3EE-5958-4920-974F-6F2DA6576D9DQ52587406-7608D5DB-AECB-4ABA-A149-F303F59D722DQ52682751-D8002E72-6F64-47C4-B3F6-E71BAEB307B8Q52684139-B5A3843F-F5C9-4F9E-87CE-1A52353DD436Q52714360-DB1D658F-EC68-4162-A8D9-F9DF0B4288B8Q52715784-4503A8B5-40B0-4A2D-A9DE-2052C6F4558DQ54109548-DAE1757A-3FC4-4B16-83B2-2E2434C4CA97Q54109659-D401440F-1F1B-4DEB-AA5D-9E538066B02AQ55020853-FB303DED-FFBE-492F-85A1-EEC6968DBCB2Q55312983-8923A9AC-A005-4070-9C59-BDF6A2DBBC84Q55378109-93C32415-434D-4215-BA1C-F127CB693EABQ55401255-66EE870D-8BD2-4950-B7AB-BC46869A5867Q55515297-2874AA81-A06E-4A78-9F2F-48F300A9C282Q55725588-310BA089-42BB-4A8B-982E-DE634A06516BQ56888965-23845359-BBD0-4349-AE85-9B0FCA61649BQ56890070-6572A424-2B83-4532-B7F4-0001F06E972BQ56893519-D473BB30-7B81-4EED-B13E-1E906C6262BBQ57162847-2C7977FA-00E2-4315-83B8-F8BBA848E0FBQ57174372-6A24FC22-4734-47C1-8DC7-B2A6DB3F69AEQ57815797-7D5D41A7-D11E-4CA4-AE4D-478F721517DDQ58562303-EE0CDD0B-D8FD-4410-B1B9-B6DBB750F510Q58562314-9D449F48-41A4-4CAC-B2DB-116ECE7EDF62
P2860
Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@en
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@nl
type
label
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@en
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@nl
prefLabel
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@en
Potential Predictive Value of ...... herapy in Lung Adenocarcinoma.
@nl
P2093
P1476
Potential Predictive Value of ...... therapy in Lung Adenocarcinoma
@en
P2093
Hai-Yan Tu
Hao-Ran Zhai
Hong-Hong Yan
Hua-Jun Chen
Jia-Xin Lin
Jin-Ji Yang
Ri-Qiang Liao
P304
P356
10.1158/1078-0432.CCR-16-2554
P407
P50
P577
2016-12-30T00:00:00Z